This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Amgen Stock is Outperforming Its Industry Of Late
by Zacks Equity Research
Favorable patent ruling related to Enbrel and strong second-quarter results drive Amgen (AMGN) stock 22.6% higher in the past three months.
J&J's Tuberculosis Drug Gets FDA Nod for Adolescent Patients
by Zacks Equity Research
FDA approves J&J's (JNJ) pulmonary multidrug-resistant tuberculosis tablet Sirturo (bedaquiline) for the treatment of adolescent patients.
Puma (PBYI) Q2 Earnings Miss, Nerlynx Sales Rise, Stock Up
by Zacks Equity Research
Puma Biotech (PBYI) incurs wider loss in Q2. Sales of Nerlynx improve from first-quarter levels. Stock rises 23%.
Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients
by Kinjel Shah
Allergan (AGN) and Novo Nordisk (NVO) report Q2 results. AbbVie's (ABBV) Maviret and Sanofi's (SNY) Dupixent receive approval for new patient population in Europe.
Radius (RDUS) Q2 Earnings Beat Estimates, Tymlos Sales Solid
by Zacks Equity Research
Radius (RDUS) reports a narrower-then-expected loss and beats sales estimates in the second quarter of 2019.
Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance
by Zacks Equity Research
Aerie (AERI) lowers its annual sales guidance and reports a narrower loss in Q2.
Mallinckrodt (MNK) Q2 Earnings Beat, Generics Spin-off on Hold
by Zacks Equity Research
Mallinckrodt (MNK) beats on earnings in Q2 but marginally misses on revenues. The company suspends plan to spin-off the generic business for now.
ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
ImmunoGen (IMGN) reports narrower-than-expected loss in the second quarter and beats revenue estimates. The company provides updated guidance for 2019.
Blueprint Medicines (BPMC) Q2 Loss Widens, Sales Top Mark
by Zacks Equity Research
Blueprint Medicines (BPMC) suffers wider-than-expected loss in the second quarter while sales beat estimates.
Exelixis (EXEL) Q2 Earnings & Sales Beat, Cabometyx Shines
by Zacks Equity Research
Exelixis (EXEL) beats on earnings and sales in the second quarter, as lead drug Cabometyx continues momentum.
Infinity (INFI) Q2 Loss Wider Than Expected, Sales Miss
by Zacks Equity Research
Infinity (INFI) posts wider-than-expected loss in the second quarter of 2019 and misses sales estimates.
The Zacks Analyst Blog Highlights: Roche, LVMH-Moet Hennessy Louis Vuitton and General Electric
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Roche, LVMH-Moet Hennessy Louis Vuitton and General Electric
Dr. Reddy's (RDY) Q1 Earnings and Revenues Increase Y/Y
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and sales increase year over year in the first quarter of fiscal 2020.
Bayer (BAYRY) Q2 Earnings Match Estimates, Sales Up Y/Y
by Zacks Equity Research
Bayer (BAYRY) reports in-line earnings in the second quarter of 2019.
A Packed Global Week Lies Ahead
by John Blank
It's going to be a busy central banking week. The BOJ and Fed meetings will be followed by the Bank of England.
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises EPS View
by Zacks Equity Research
AbbVie (ABBV) beats second-quarter estimates for both earnings and revenues. Biosimilar competition impacts Humira sales in ex-U.S. markets. Growth in Imbruvica sales offsets Humira decline.
Can Newer Drugs Help Amgen (AMGN) Beat on Earnings in Q2?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products are likely to put pressure on second-quarter sales.
Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment
by Kinjel Shah
AstraZeneca (AZN), Roche (RHHBY), Bristol-Myers (BMY) and Glaxo (GSK) report Q2 results. FDA approves Lilly's (LLY) nasal glucagon to treat severe hypoglycemia.
AstraZeneca (AZN) Q2 Earnings Top, '19 Product Sales View Up
by Zacks Equity Research
AstraZeneca (AZN) beats estimates for earnings and sales. New drugs, mainly cancer medicines, lead to high product sales.
Roche (RHHBY) 1H19 Earnings & Sales Up Y/Y, View Raised
by Zacks Equity Research
Roche's (RHHBY) performance in the first half of 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.
Large-Cap Pharmaceuticals Industry Near-Term Outlook Bright
by Kinjel Shah
The Zacks Large Cap Pharmaceuticals industry underperforms the sector and S&P 500. However it ranks in the top 19% of more than 250 Zacks industries.
Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q2 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Opdivo and Eliquis along with updates on the Celgene merger, when Bristol-Myers (BMY) reports second-quarter results.
Biogen (BIIB) Up on Q2 Earnings & Sales Beat, Raised View
by Zacks Equity Research
Biogen (BIIB) reports encouraging second-quarter results. Shares rise in pre-market trading.
Will Humira & Other Drugs Drive AbbVie's (ABBV) Q2 Earnings?
by Zacks Equity Research
Steady rise in demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.
Bristol-Myers, Ono, Bayer Team Up for Colorectal Cancer Study
by Zacks Equity Research
Bristol-Myers (BMY), Ono Pharmaceutical and Bayer ink a collaboration deal to evaluate the combination of Opdivo plus Stivarga for treating micro-satellite stable metastatic colorectal cancer.